Drs Jane Visvader and Geoff Lindeman, researchers at Melbournes Walter and Eliza Hall Institute (WEHI) and the Royal Melbourne Hospital, have been presented with the GlaxoSmithKline Award for Research Excellence for their outstanding contribution to breast cancer research.
Regarded as one of the most prestigious within the Australian research community, the award recognises the outstanding contribution by the pair in advancing international understanding of breast cancer.
The Award recognises their body of work, where several research outcomes have taken on international significance:
Their teams discovery of the breast stem cell laid an important foundation for understanding how normal breast tissue develops and is likely to provide clues about how breast cancer develops and how rogue cells evade current therapies. It is likely to form the basis of international research in breast cancer for years to come. The discovery of a luminal precursor breast cell, which forms part of the hierarchy of cells in breast tissue. This cell may be a key target for mutation in the majority of breast cancers.
The demonstration that LMO4 and GATA-3 are key regulators in breast tissue: overproduction of LMO4 leads to breast cancer; while GATA-3 is a critical factor for driving maturation of breast ductal cells and is an important suppressor of breast tumours.
The ultimate goal of our research is to identify the cells and molecular pathways that are responsible for sustaining tumours. If we can achieve this, then we should be able to develop more effective prognostic markers, and importantly, novel targeted therapies, said Dr Jane Visvader.
Dr Geoff Lindeman said, We are deeply honoured to receive this award and recognition from GSK, cognisant of how much excellent medical research is being carried out in Australia. Research is necessarily a team effort, and this award reflects on the talented people with whom we have
|Contact: Brad Allan|